Respiratory devices maker Vectura Group PLC (LON:VEC) has signed an exclusive global agreement with Dynavax Technologies Corporation (NASDAQ:DVAX), a clinical-stage immunotherapy company.
The collaboration will see Vectura's AKITA smart nebuliser used by Dynavax to deliver DV281, a protein that triggers an immunity response, designed specifically for local delivery to primary lung tumours.
READ: Vectura reports wider loss but revenue jumps after Skyepharma merger
The agreement covers the Phase I and Phase II development programmes. Vectura will provide devices and device related support to Dynavax, which is responsible for the rest of the programme.
Vectura does not expect this to result in a material impact on research & development expenditure this year and next.
“The collaboration with Dynavax is an exciting innovative programme combining the development of a new treatment option for patients with lung cancer along with targeted inhaled delivery,” claimed James Ward-Lilley, Vectura's chief executive officer.
“This agreement underlines the increasing recognition of the utility of Vectura's unique smart nebuliser technology and devices by existing and potential development partners," he added.
Shares in Vectura were up 1.25 at 113.9p.